Japan Price Reforms Will Be Pro-Innovation, Inclusive - Official
Executive Summary
A Japanese official provides reassurances at BIO Asia that the government intends to abide by drug pricing policies that support innovation, although the research-based pharma industry remains concerned that sweeping reforms now under discussion may hamper R&D and investment in the country.
You may also be interested in...
Indian Generics Firms Must Shift Gears For Third Wave, Says Lupin MD
Indian firms must transition from “plain-vanilla” generics to more complex products, including biosimilars, if they want to continue growing. However, returns from the sector’s so-called Third Wave will be some time coming, warns Lupin’s managing director Nilesh Gupta.
Indian Generics Firms Must Shift Gears For Third Wave, Says Lupin MD
Indian firms must transition from “plain-vanilla” generics to more complex products, including biosimilars, if they want to continue growing. However, returns from the sector’s so-called Third Wave will be some time coming, warns Lupin’s managing director Nilesh Gupta.
Japan Pricing Reform Process Must Be Participative – Pfizer
Against a background of ongoing discussions in Japan over the reform of the drug pricing and reimbursement system, Pfizer is calling for greater industry participation and recognition of the value of innovation.